AstraZeneca PLC $AZN Shares Purchased by Cubist Systematic Strategies LLC

Cubist Systematic Strategies LLC raised its stake in AstraZeneca PLC (NASDAQ:AZN) by 106.2% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 484,078 shares of the company’s stock after buying an additional 249,364 shares during the period. Cubist Systematic Strategies LLC’s holdings in AstraZeneca were worth $33,827,000 as of its most recent filing with the SEC.

Several other large investors have also modified their holdings of AZN. Pekin Hardy Strauss Inc. boosted its position in AstraZeneca by 4.2% during the 2nd quarter. Pekin Hardy Strauss Inc. now owns 3,650 shares of the company’s stock worth $255,000 after buying an additional 148 shares during the period. Richardson Financial Services Inc. raised its stake in shares of AstraZeneca by 59.8% during the second quarter. Richardson Financial Services Inc. now owns 398 shares of the company’s stock valued at $28,000 after acquiring an additional 149 shares during the last quarter. Evergreen Capital Management LLC lifted its holdings in shares of AstraZeneca by 0.7% during the first quarter. Evergreen Capital Management LLC now owns 23,709 shares of the company’s stock worth $1,743,000 after purchasing an additional 155 shares during the period. Grimes & Company Inc. lifted its holdings in shares of AstraZeneca by 3.0% during the second quarter. Grimes & Company Inc. now owns 5,290 shares of the company’s stock worth $370,000 after purchasing an additional 155 shares during the period. Finally, Gerber Kawasaki Wealth & Investment Management grew its stake in shares of AstraZeneca by 5.2% in the second quarter. Gerber Kawasaki Wealth & Investment Management now owns 3,174 shares of the company’s stock worth $222,000 after purchasing an additional 158 shares during the last quarter. 20.35% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several research analysts have commented on the company. Morgan Stanley reaffirmed an “overweight” rating and set a $103.00 target price on shares of AstraZeneca in a report on Wednesday, December 3rd. Jefferies Financial Group started coverage on AstraZeneca in a research note on Monday, October 27th. They issued a “buy” rating on the stock. Guggenheim reissued a “buy” rating on shares of AstraZeneca in a research report on Wednesday, December 3rd. Deutsche Bank Aktiengesellschaft lowered shares of AstraZeneca from a “hold” rating to a “sell” rating in a report on Thursday, October 16th. Finally, HSBC reaffirmed a “buy” rating and issued a $108.00 price objective on shares of AstraZeneca in a research note on Wednesday. Eight investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $95.75.

AstraZeneca Trading Down 0.5%

NASDAQ AZN opened at $89.83 on Friday. The stock has a market capitalization of $278.60 billion, a P/E ratio of 29.84, a P/E/G ratio of 1.67 and a beta of 0.32. The business has a 50 day simple moving average of $87.03 and a 200 day simple moving average of $79.11. The company has a debt-to-equity ratio of 0.54, a current ratio of 0.88 and a quick ratio of 0.69. AstraZeneca PLC has a one year low of $61.24 and a one year high of $94.01.

AstraZeneca (NASDAQ:AZN) last posted its quarterly earnings results on Thursday, November 6th. The company reported $1.19 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.14 by $0.05. The firm had revenue of $15.19 billion for the quarter, compared to analysts’ expectations of $14.75 billion. AstraZeneca had a return on equity of 32.89% and a net margin of 16.17%.The company’s revenue for the quarter was up 12.0% compared to the same quarter last year. During the same period in the prior year, the business earned $2.08 EPS. Research analysts expect that AstraZeneca PLC will post 4.51 earnings per share for the current year.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.